Cargando…
Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro
Lung cancer is one of the main causes of cancer-related deaths. At present, the main treatment method for lung cancer is chemotherapy. Gemcitabine (GEM) is widely applied in lung cancer treatment, but its lack of targeting ability and serious side effects limit its application. In recent years, nano...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059217/ https://www.ncbi.nlm.nih.gov/pubmed/36986849 http://dx.doi.org/10.3390/pharmaceutics15030988 |
_version_ | 1785016821444771840 |
---|---|
author | Tang, Huan Zhang, Zheng Zhu, Ming Xie, Yizhuo Lv, Zhe Liu, Rui Shen, Yujia Pei, Jin |
author_facet | Tang, Huan Zhang, Zheng Zhu, Ming Xie, Yizhuo Lv, Zhe Liu, Rui Shen, Yujia Pei, Jin |
author_sort | Tang, Huan |
collection | PubMed |
description | Lung cancer is one of the main causes of cancer-related deaths. At present, the main treatment method for lung cancer is chemotherapy. Gemcitabine (GEM) is widely applied in lung cancer treatment, but its lack of targeting ability and serious side effects limit its application. In recent years, nanocarriers have become the focus of research to solve the above problems. Here, we prepared estrone (ES)-modified GEM-loaded PEGylated liposomes (ES-SSL-GEM) for enhanced delivery by identifying the overexpressed estrogen receptor (ER) on lung cancer A549 cells. We studied the characterization, stability, release behavior, cytotoxicity, targeting ability, endocytosis mechanism, and antitumor ability to prove the therapeutic effect of ES-SSL-GEM. The results showed that ES-SSL-GEM presented a uniform particle size of 131.20 ± 0.62 nm, a good stability, and a slowly released behavior. Moreover, ES-SSL-GEM enhanced tumor-targeting ability, and the endocytosis mechanism studies confirmed that the ER-mediated endocytosis had the most crucial effect. Furthermore, ES-SSL-GEM had the best inhibitory effect on A549 cell proliferation and significantly suppressed the tumor growth in vivo. These results suggest that ES-SSL-GEM is a promising agent for treating lung cancer. |
format | Online Article Text |
id | pubmed-10059217 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100592172023-03-30 Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro Tang, Huan Zhang, Zheng Zhu, Ming Xie, Yizhuo Lv, Zhe Liu, Rui Shen, Yujia Pei, Jin Pharmaceutics Article Lung cancer is one of the main causes of cancer-related deaths. At present, the main treatment method for lung cancer is chemotherapy. Gemcitabine (GEM) is widely applied in lung cancer treatment, but its lack of targeting ability and serious side effects limit its application. In recent years, nanocarriers have become the focus of research to solve the above problems. Here, we prepared estrone (ES)-modified GEM-loaded PEGylated liposomes (ES-SSL-GEM) for enhanced delivery by identifying the overexpressed estrogen receptor (ER) on lung cancer A549 cells. We studied the characterization, stability, release behavior, cytotoxicity, targeting ability, endocytosis mechanism, and antitumor ability to prove the therapeutic effect of ES-SSL-GEM. The results showed that ES-SSL-GEM presented a uniform particle size of 131.20 ± 0.62 nm, a good stability, and a slowly released behavior. Moreover, ES-SSL-GEM enhanced tumor-targeting ability, and the endocytosis mechanism studies confirmed that the ER-mediated endocytosis had the most crucial effect. Furthermore, ES-SSL-GEM had the best inhibitory effect on A549 cell proliferation and significantly suppressed the tumor growth in vivo. These results suggest that ES-SSL-GEM is a promising agent for treating lung cancer. MDPI 2023-03-19 /pmc/articles/PMC10059217/ /pubmed/36986849 http://dx.doi.org/10.3390/pharmaceutics15030988 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Tang, Huan Zhang, Zheng Zhu, Ming Xie, Yizhuo Lv, Zhe Liu, Rui Shen, Yujia Pei, Jin Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro |
title | Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro |
title_full | Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro |
title_fullStr | Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro |
title_full_unstemmed | Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro |
title_short | Efficient Delivery of Gemcitabine by Estrogen Receptor-Targeted PEGylated Liposome and Its Anti-Lung Cancer Activity In Vivo and In Vitro |
title_sort | efficient delivery of gemcitabine by estrogen receptor-targeted pegylated liposome and its anti-lung cancer activity in vivo and in vitro |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10059217/ https://www.ncbi.nlm.nih.gov/pubmed/36986849 http://dx.doi.org/10.3390/pharmaceutics15030988 |
work_keys_str_mv | AT tanghuan efficientdeliveryofgemcitabinebyestrogenreceptortargetedpegylatedliposomeanditsantilungcanceractivityinvivoandinvitro AT zhangzheng efficientdeliveryofgemcitabinebyestrogenreceptortargetedpegylatedliposomeanditsantilungcanceractivityinvivoandinvitro AT zhuming efficientdeliveryofgemcitabinebyestrogenreceptortargetedpegylatedliposomeanditsantilungcanceractivityinvivoandinvitro AT xieyizhuo efficientdeliveryofgemcitabinebyestrogenreceptortargetedpegylatedliposomeanditsantilungcanceractivityinvivoandinvitro AT lvzhe efficientdeliveryofgemcitabinebyestrogenreceptortargetedpegylatedliposomeanditsantilungcanceractivityinvivoandinvitro AT liurui efficientdeliveryofgemcitabinebyestrogenreceptortargetedpegylatedliposomeanditsantilungcanceractivityinvivoandinvitro AT shenyujia efficientdeliveryofgemcitabinebyestrogenreceptortargetedpegylatedliposomeanditsantilungcanceractivityinvivoandinvitro AT peijin efficientdeliveryofgemcitabinebyestrogenreceptortargetedpegylatedliposomeanditsantilungcanceractivityinvivoandinvitro |